AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24754350 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 52
Study 22762347 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm × 32 G pen needle
Number of subjects: 168
Study 22762347 — intervention group
Group type: COMPARATOR
Intervention: 5 mm pen needle
Number of subjects: 168
Study 22762347 — intervention group
Group type: COMPARATOR
Intervention: 8 mm pen needle
Number of subjects: 168
Study 22762347 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm pen needle
Number of subjects: 168
Study 20740615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) for 1 year
Number of subjects: 158
Study 20740615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 20740615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 158
Study 18071252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassis polysaccharide (CAPS)
Number of subjects: 28
Study 18071252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15776298 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt tapered needle
Number of subjects: 200
Study 15776298 — intervention group
Group type: COMPARATOR
Intervention: Sharp needle
Number of subjects: 200
Study 11976244 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment (omeprazole 20 mg, metronidazole 500 mg, and clarithromycin 250 mg for 7 days)
Number of subjects: 294
Study 11976244 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (omeprazole 20 mg, placebo metronidazole, and placebo clarithromycin for 7 days)
Number of subjects: 294
Study 11976244 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment
Number of subjects: 294
Study 11976244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients negative for H pylori
Number of subjects: 294
Study 11976244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients positive for H pylori
Number of subjects: 294
Study 9917775 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK for myopia correction
Number of subjects: 574
Study 7896490 — intervention group
Group type: EXPERIMENTAL
Intervention: estriol iontophoresis
Number of subjects: 46
Study 7896490 — intervention group
Group type: EXPERIMENTAL
Intervention: tretinoin iontophoresis
Number of subjects: 46
Study 1696577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antithrombin III and heparin
Number of subjects: 0
Study 1696577 — intervention group
Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 0
Study 7016248 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% podophyllin
Number of subjects: 140
Study 7016248 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% podophyllin
Number of subjects: 140
Study 7016248 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin treatment (10% and 25%)
Number of subjects: 140
Study 31619437 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg amoxicillin three times daily for three months
Number of subjects: 180
Study 31619437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 29037637 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (30 min per day, twice a week for 12 weeks)
Number of subjects: 34
Study 29037637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 34
Study 25646368 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio0932 at a dose of 1000 mg daily
Number of subjects: 50
Study 25646368 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio0932 at doses up to 1600 mg
Number of subjects: 50
Study 25646368 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio0932
Number of subjects: 50
Study 25189750 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from the system
Number of subjects: 16
Study 25189750 — intervention group
Group type: COMPARATOR
Intervention: No feedback from the system
Number of subjects: 16
Study 23061323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing counseling and methadone maintenance therapy
Number of subjects: 0
Study 20083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Number of subjects: 42
Study 20083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate
Number of subjects: 42
Study 20083724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17377586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide, doxorubicin, and dexamethasone (TAD)
Number of subjects: 398
Study 17377586 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and dexamethasone (VAD)
Number of subjects: 398
Study 17377586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide as part of induction regimen
Number of subjects: 398
Study 17377586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide patients
Number of subjects: 398
Study 15934353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber 7 supplement (7 g per meal twice a day)
Number of subjects: 92
Study 12447093 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections
Number of subjects: 0
Study 12447093 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with steroid
Number of subjects: 0
Study 12447093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10452746 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming of feet in warm water (WW, 42 degrees C)
Number of subjects: 14
Study 10452746 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature water (RW, 30 degrees C)
Number of subjects: 14
Study 7844484 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMSTIM program with anxiety-laden words (experimental group)
Number of subjects: 40
Study 7844484 — intervention group
Group type: COMPARATOR
Intervention: HEMSTIM program with neutral words (control group)
Number of subjects: 40
Study 2189591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16) 100, 150, or 225 mg/m2 infused over 2 h into the pleural space after drainage of pleural fluid
Number of subjects: 10
Study 2189591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16) 225 mg/m2
Number of subjects: 10
Study 2189591 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16)
Number of subjects: 10
Study 7288177 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 19200
Study 7288177 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 19200
Study 7288177 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongly tuberculin-positive (Heaf Grades III-IV) children
Number of subjects: 19200
Study 31751828 — intervention group
Group type: EXPERIMENTAL
Intervention: PM10 during dust days
Number of subjects: 0
Study 31751828 — intervention group
Group type: COMPARATOR
Intervention: PM10 during non-dust days
Number of subjects: 0
Study 31751828 — intervention group
Group type: COMPARATOR
Intervention: PM10 during dust days in Tehran
Number of subjects: 0
Study 31751828 — intervention group
Group type: COMPARATOR
Intervention: PM10 during non-dust days in Tehran
Number of subjects: 0
Study 31751828 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 during non-dust days in Tehran at lag 2
Number of subjects: 0
Study 31751828 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 during non-dust days in Tehran at lag 3
Number of subjects: 0
Study 31751828 — intervention group
Group type: COMPARATOR
Intervention: PM2.5 in Ahvaz
Number of subjects: 0
Study 30358864 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2-mA for 20 minutes/session, 10 sessions)
Number of subjects: 21
Study 30358864 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study 27984230 — intervention group
Group type: COMPARATOR
Intervention: Wound Infiltration (15 mL of bupivacaine 0.25% in each side of the surgical wound, total 30 mL)
Number of subjects: 80
Study 27984230 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) Block (20 mL of bupivacaine 0.25% bilaterally, total 40 mL)
Number of subjects: 80
Study 27984230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Wound Infiltration and TAP Block)
Number of subjects: 80
Study 26216675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 10 mg, bid for 3 months
Number of subjects: 120
Study 26216675 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg, bid for 3 months
Number of subjects: 120
Study 26216675 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TAM and Indomethacin
Number of subjects: 120
Study 24036568 — intervention group
Group type: EXPERIMENTAL
Intervention: mCABG
Number of subjects: 60
Study 24036568 — intervention group
Group type: COMPARATOR
Intervention: cCABG
Number of subjects: 60
Study 20801436 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TTG) pretreatment, 12.5 mg applied daily for 21 days before COS
Number of subjects: 110
Study 20801436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TTG pretreatment)
Number of subjects: 110
Study 19373657 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/d, with dose escalation up to 1000 mg/d over 60 days)
Number of subjects: 28
Study 17302070 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuangfujin (SFJ)
Number of subjects: 120
Study 17302070 — intervention group
Group type: COMPARATOR
Intervention: Boric acid
Number of subjects: 120
Study 17302070 — intervention group
Group type: COMPARATOR
Intervention: Pifukang lotion
Number of subjects: 120
Study 17302070 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study 16476934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ), maximum dosage of 100 mg/day for 12 weeks
Number of subjects: 84
Study 16476934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 12627850 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (lenograstim)
Number of subjects: 84
Study 10784622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus G-CSF (regimen C)
Number of subjects: 29
Study 10784622 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor plus G-CSF (regimen G)
Number of subjects: 29
Study 8980158 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 13
Study 1459878 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise training program (8 weeks)
Number of subjects: 40
Study 1459878 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 40
Study 6501754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient intakes of white girls
Number of subjects: 1247
Study 6501754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient intakes of urban girls
Number of subjects: 1247
Study 6501754 — intervention group
Group type: EXPERIMENTAL
Intervention: Folacin intake
Number of subjects: 1247
Study 6501754 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and magnesium intakes
Number of subjects: 1247
Study 6501754 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall nutrient intake
Number of subjects: 1247
Study 6501754 — intervention group
Group type: EXPERIMENTAL
Intervention: Folacin, iodine, vitamin D, iron, calcium, vitamin B-6, zinc, magnesium, and vitamin A intakes
Number of subjects: 1247
Study 30238430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 240
Study 28513635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate supplementation for 15 days
Number of subjects: 110
Study 28513635 — intervention group
Group type: COMPARATOR
Intervention: Placebo chocolate
Number of subjects: 110
Study 24583745 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocut mode (E‐mode)
Number of subjects: 360
Study 24583745 — intervention group
Group type: COMPARATOR
Intervention: Conventional blended cut mode (C‐mode)
Number of subjects: 360
Study 24254262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Number of subjects: 279
Study 24254262 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Number of subjects: 279
Study 21875224 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (believed to be methylphenidate)
Number of subjects: 96
Study 21875224 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 96
Study 18357535 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior practice with simulated machine operation
Number of subjects: 0
Study 18357535 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback interpretation following simulations
Number of subjects: 0
Study 17225018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucicort Lipid cream
Number of subjects: 629
Study 17225018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucicort cream
Number of subjects: 629
Study 17225018 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 629
Study 14717749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation scintigraphy after inhalation of technegas
Number of subjects: 20
Study 14717749 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 20
Study 11771086 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-septal approach to the mitral valve
Number of subjects: 40
Study 11771086 — intervention group
Group type: COMPARATOR
Intervention: Standard left atriotomy
Number of subjects: 40
Study 11771086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 9222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox (30 mL) with trovafloxacin (100 mg)
Number of subjects: 12
Study 9222077 — intervention group
Group type: COMPARATOR
Intervention: Placebo with trovafloxacin (100 mg)
Number of subjects: 12
Study 9222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox (30 mL) 2 h before trovafloxacin (100 mg)
Number of subjects: 12
Study 9222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg) with trovafloxacin (100 mg)
Number of subjects: 12
Study 8240996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (EP)
Number of subjects: 62
Study 8240996 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus etoposide (EC)
Number of subjects: 62
Study 3316304 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 152
Study 3316304 — intervention group
Group type: COMPARATOR
Intervention: Clonidine HCl
Number of subjects: 152
Study 28668998 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-Zinc-Calcium-Vitamin D co-supplementation (100 mg magnesium, 4 mg zinc, 400 mg calcium, 200 IU vitamin D, twice a day for 12 weeks)
Number of subjects: 60
Study 28668998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day for 12 weeks)
Number of subjects: 60
Study 27599002 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex and gutta‐percha (group 1)
Number of subjects: 34
Study 27599002 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus and gutta‐percha (group 2)
Number of subjects: 34
Study 27599002 — intervention group
Group type: COMPARATOR
Intervention: MTA Fillapex
Number of subjects: 34
Study 25651427 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab + R-ICE
Number of subjects: 151
Study 25651427 — intervention group
Group type: COMPARATOR
Intervention: Placebo + R-ICE
Number of subjects: 151
Study 25651427 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent autologous stem cell transplant
Number of subjects: 151
Study 24029165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarettes (16 mg)
Number of subjects: 657
Study 24029165 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches (21 mg, one daily)
Number of subjects: 657
Study 24029165 — intervention group
Group type: COMPARATOR
Intervention: Placebo e‐cigarettes (no nicotine)
Number of subjects: 657
Study 24029165 — intervention group
Group type: COMPARATOR
Intervention: Nicotine e‐cigarettes vs patches
Number of subjects: 657
Study 24029165 — intervention group
Group type: COMPARATOR
Intervention: Nicotine e‐cigarettes vs placebo e‐cigarettes
Number of subjects: 657
Study 24029165 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 657
Study 21086021 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 201
Study 21086021 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 201
Study 18997543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl-Guar (Systane)
Number of subjects: 12
Study 18997543 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 12
Study 17058847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Salmeterol/Fluticasone 50/250 mg for 6 weeks
Number of subjects: 12
Study 17058847 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol first or Fluticasone first for 4 weeks each
Number of subjects: 12
Study 12752647 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyde File Prep with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Number of subjects: 39
Study 12752647 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 17% EDTA
Number of subjects: 39
Study 12752647 — intervention group
Group type: COMPARATOR
Intervention: 1% NaOCl with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Number of subjects: 39
Study 11084130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein tension‐free hernioplasty (LH)
Number of subjects: 30
Study 11084130 — intervention group
Group type: COMPARATOR
Intervention: Conventional Bassini hernia repair (BH)
Number of subjects: 30
Study 9112326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain for chemonucleolysis
Number of subjects: 0
Study 9112326 — intervention group
Group type: COMPARATOR
Intervention: Chymopapain injection
Number of subjects: 0
Study 9112326 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase for chemonucleolysis
Number of subjects: 0
Study 9112326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitinase ABC
Number of subjects: 0
Study 1602608 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted platelet concentrates prepared through a polyester platelet filter (Sepacell-PL)
Number of subjects: 72
Study 1602608 — intervention group
Group type: COMPARATOR
Intervention: Standard platelet concentrates (control group)
Number of subjects: 72
Study 3912977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 10 mg/kg, 8‐hourly for 10 days
Number of subjects: 127
Study 3912977 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine 15 mg/kg daily for 10 days
Number of subjects: 127
Study 30900380 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness-based intervention (MBI)
Number of subjects: 143
Study 29876926 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated praise
Number of subjects: 105
Study 29876926 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest praise
Number of subjects: 105
Study 29876926 — intervention group
Group type: COMPARATOR
Intervention: No praise
Number of subjects: 105
Study 27687452 — intervention group
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP
Number of subjects: 24
Study 27687452 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask
Number of subjects: 24
Study 27687452 — intervention group
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP and Venturi mask
Number of subjects: 24
Study 24629989 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d for 30 days (group 1)
Number of subjects: 99
Study 24629989 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg/d for 30 days (group 2)
Number of subjects: 99
Study 24629989 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d (group 1)
Number of subjects: 99
Study 24629989 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d (group 2)
Number of subjects: 99
Study 24629989 — intervention group
Group type: COMPARATOR
Intervention: Both groups (1 and 2)
Number of subjects: 99
Study 22187203 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-11355
Number of subjects: 122
Study 22187203 — intervention group
Group type: COMPARATOR
Intervention: Zinostatin stimalamer
Number of subjects: 122
Study 20683333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane volatile induction/maintenance anaesthesia (Group VIMA)
Number of subjects: 64
Study 20683333 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil total intravenous anaesthesia (Group TIVA)
Number of subjects: 64
Study 19167593 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 (8-hour IV infusion with a 1-hour loading dose at 3x maintenance rate)
Number of subjects: 36
Study 19167593 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 36
Study 19167593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 36
Study 15891344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-midazolam
Number of subjects: 30
Study 15891344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-midazolam
Number of subjects: 30
Study 12651648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (Zingiber officinale)
Number of subjects: 180
Study 11340136 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated biopsy device
Number of subjects: 56
Study 11340136 — intervention group
Group type: COMPARATOR
Intervention: Aspiration technique
Number of subjects: 56
Study 9175409 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire with four pages (22 questions)
Number of subjects: 3000
Study 9175409 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire with eight pages (35 questions)
Number of subjects: 3000
Study 9175409 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up mailings
Number of subjects: 3000
Study 8242282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 2.5 l of a 2.5% glucose/0.45% NaCl solution
Number of subjects: 66